Organization (Industry)
Human Genome Sciences (United States)
ClinicalTrials.gov lists Human Genome Sciences (United States) as lead sponsor of 23 trials. It has 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Human Genome Sciences (United States): 23 lead-sponsored trials and 1 legal-entity registration.
Disease areas (23)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lupus Erythematosus, Systemic | 9 |
| Hepatitis C | 6 |
| Hepatitis C, Chronic | 5 |
| Arthritis, Rheumatoid | 3 |
| Bronchiolitis | 2 |
Showing 5 of 23 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2012 | 2 |
| 2011 | 3 |
| 2010 | 3 |
| 2009 | 4 |
| 2008 | 5 |
| 2007 | 3 |
| 2006 | 3 |
| 2005 | 4 |
| 2004 | 2 |
| 2003 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 23 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ribavirin | 5 |
| Raxibacumab | 2 |
| PEGinterferon alfa-2a | 2 |
| Belimumab | 2 |
| BORTEZOMIB | 1 |
Showing 5 of 7 approved assets.
Journals published in (41)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Arthritis and rheumatism | 9 |
| Rheumatology (Oxford, England) | 6 |
| The Journal of experimental medicine | 4 |
| Annals of the rheumatic diseases | 3 |
| Arthritis research & therapy | 3 |
Showing 5 of 41 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 711 | 0 | 2016-08-02 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 7 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Human Genome Sciences, Inc. | Rockville, US | FDA, Health Canada |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Hospital for Special Surgery, New York | Co sponsors trial with | 1 |
Latest dated events (750)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-07-31 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2018-08-30 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2016-08-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2016-04-11 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2016-03-29 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 750 events.
Biomarker capability evidence (76)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| APOH | Trial collaborator | Named in trial inclusion criteria |
| CCR5 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| HGS | Trial sponsor | Named in trial inclusion criteria |
| HLA-C | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 76 evidence rows.
On Scientist.com
Human Genome Sciences (United States) is listed as a research supplier in the Scientist.com network.
Service areas
Human Genome Sciences offers recombinant proteins, antibodies, cell culture, cell banking, purification, and manufacturing services.
- Website
- www.hgsi.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Human Genome Sciences on Scientist.com
For prices, more details, or to contact Human Genome Sciences, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.